Introduction
============

Thyroid cancer (TC) is the most common endocrine malignancy and a complex disease with a largely unknown aetiology.[@b1] TC is characterised by one of the strongest familial relative risks in cancer. First degree relatives of TC patients are up to 8.6 times more likely to develop TC than the general population.[@b2] Most of the genetic variation associated with TC remains uncharacterised, and it is likely to be explained by variants of moderate or low penetrance.

A number of recent studies have identified single nucleotide polymorphisms (SNPs) associated with TC risk on chromosomes 5q24, 8q24, 9q22, and 14q13.[@b3; @b4; @b5; @b6] Two of these SNPs, rs965513 (9q22) and rs944289 (14q13), were found through a multi-stage, genome-wide association (GWA) study in the Icelandic population.[@b3] Subsequent replication of association was found in smaller sample sets from Ohio, USA and Spain.

The other three TC SNPs were discovered through candidate gene or SNP approaches.[@b4; @b5; @b6] rs2910164 (5q24) was chosen because it lay within pre-miR-146a, a microRNA upregulated in TC. An association with TC was found in samples from Poland, Finland and Ohio, and the C allele at rs2910164 was found to decrease levels of pre- and mature miR-146A.[@b4] rs6983267 (8q24) is associated with the risk of several cancers, including those of the prostate, colon and ovary, and was assessed as a TC SNP for this reason. It showed a borderline significant association with TC in the Polish population.[@b6] rs1867277 was studied because it lies in the 5′ UTR of *FOXE1* (or *Thyroid Transcription Factor 2*), a key gene involved in thyroid organogenesis.[@b7] rs1867277 and rs965513 are in moderate pairwise linkage disequilibrium (LD) in Europeans (*r^2^*=0.39, *D*\'=0.73, <http://www.1000genomes.org/>). rs1867277 was strongly associated with TC risk in Spanish and Italian cohorts.[@b5] None of the three candidate SNP associations has been replicated in independent studies.

The aim of this study was to examine these five TC SNPs in a relatively large UK case--control sample set, to validate or refute their associations with TC in this population, and to estimate the proportion of the familial risk of TC for which they account.

Patients and methods
====================

Study samples
-------------

We recruited 781 white UK patients of northern European origin with histologically confirmed non-medullary TC through the Thyroid Cancer Genetic investigation in the UK (TCUKIN) study. In addition to obtaining standard clinicopathological information from medical records and a questionnaire completed by each patient, the participants donated a blood sample which was used to isolate genomic DNA. The Southampton and South West Hampshire Research Ethics Committee (A) approved the TCUKIN protocol.

SNP genotyping and control genotype data
----------------------------------------

We genotyped the TCUKIN samples at the five SNPs (rs2910164, rs6983267, rs965513, rs1867277, rs944289) using the KAspar system. Probes used to genotype these polymorphisms are shown in supplementary table 1. For comparison, we used available genotype data from 5193 population controls belonging to the National Blood Donor Service (NBS) and the 1958 Birth Cohort (BC58) and 929 cancer-free controls from our COloRectal Gene Identification study (CORGI). The NBS and BC58 samples had been genotyped with Illumina 1.2M (Hap1.2M) arrays as part of the Wellcome Trust Case Control Consortium 2,[@b8] and the CORGI controls had been genotyped with Illumina Hap550 arrays (Hap550, N=932) as part of our ongoing studies in colorectal cancer genetics.[@b9] Two of the five SNPs (rs2910164 and rs1867277) were not included on the Illumina 1.2M and Hap550 arrays, but had excellent proxy markers that facilitated their imputation. rs2910164 is perfectly tagged (*D*\'=1, *r^2^*=1) by rs2961920, a marker present on both SNP arrays; and rs1867277 is perfectly tagged on the Hap550s by rs1443434 and on the Hap1.2Ms by rs1867278, rs1443434, rs1443435, and rs12348691. These genotypes were imputed using IMPUTE2[@b10]; all markers had proper_info scores \>0.8 and imputation call rates \>0.95, suggesting excellent imputation. In order to confirm this excellent tagging/imputation, 94 CORGI controls were genotyped for the TC SNPs using KAspar, resulting in no discordant genotypes for each SNP, whether typed or imputed.

Quality control and statistical analysis
----------------------------------------

General genotyping quality control assessment was as previously described.[@b9] Duplicate samples were used to check genotyping quality and 100% concordance was found. Samples with multiple missing genotypes were eliminated from the analyses (N=14). All five SNPs passed our quality control thresholds including call rates \>95% and Hardy-Weinberg equilibrium p values \>0.05.[@b11]

Association statistics were obtained on per allele, genotypic and haplotype bases using logistic regression models implemented in PLINK, R, and SNPTEST.[@b12] [@b13] Haplotype analyses were carried out with HAPLOVIEW[@b14] and PLINK. Allelic count association meta-analyses, using the Mantel-Haenszel method, were carried out in STATA. We used the IMPUTE2 software[@b10] formally to generate rs2910164 and rs1867277 genotypes in the control population, although the fact that perfect proxies were used rendered this task of very limited utility.[@b10] To test for independence between SNPs, we used conditional logistic regression models. The proportion of the familial relative risk explained by the polymorphisms investigated in the study was estimated using the method reported by Houlston *et al*.[@b15]

Results
=======

Single SNP analyses
-------------------

Three of the five SNPs examined showed a significant association with TC risk in the UK population ([table 1](#tbl1){ref-type="table"}). The strongest associations, on a per allele basis, were observed for the 9q22 SNPs rs965513A (p=6.35×10^−34^, OR=1.99, 95% CI 1.77 to 2.21) and rs1867277A (p=5.90×10^−24^, OR=1.75, 95% CI 1.57 to 1.95). The association at rs944289T on 14q13 was also convincingly replicated (p=6.95×10^−7^, OR=1.33, 95% CI 1.18 to 1.48). For rs6983267G, we also found a nominally significant association with TC risk (p=0.016, OR=1.14, 95% CI 1.02 to 1.27, equivalent false discovery rate=0.020). However, the association between TC and rs2910164 was not replicated (P~allelic~=0.85, OR=1.01, 95% CI 0.89 to 1.14). To test if the strength of these associations were similar in cases with different histological types, we carried out cases-only interaction analyses. We found no differences between cases with papillary and follicular histology (p\>0.25 for all markers, data not shown), suggesting that these associations were not restricted to any particular histological type of TC.

###### 

Association statistics for thyroid cancer risk and genetic variants at chromosomes 5q24, 8q24, 9q22 and 14q13

  SNP, genotypes and risk allele   Frequency (%)   ORs for genotype or per allele overall (95% CI)   p Value                  
  -------------------------------- --------------- ------------------------------------------------- ------------------------ --------------
  rs2910164                                                                                                                   
   GG                              436 (0.578)     3540 (0.584)                                      Reference                
   CG                              271 (0.367)     2179 (0.360)                                      1.032 (0.876 to 1.214)   0.728
   CC                              41 (0.054)      339 (0.056)                                       0.987 (0.682 to 1.384)   0.985
   Risk allele (C)                 359 (0.238)     2857 (0.236)                                      1.013 (0.893 to 1.148)   0.845
  rs6983267                                                                                                                   
   TT                              164 (0.218)     1441 (0.236)                                      Reference                
   GT                              346 (0.461)     3012 (0.493)                                      1.010 (0.827 to 1.236)   0.960
   GG                              241 (0.321)     1662 (0.272)                                      1.274 (1.027 to 1.583)   0.026
   Risk allele (G)                 674 (0.449)     5894 (0.518)                                      1.140 (1.025 to 1.268)   0.016
  rs965513                                                                                                                    
   GG                              187 (0.249)     2748 (0.449)                                      Reference                
   AG                              394 (0.525)     2729 (0.446)                                      2.121 (1.763 to 2.559)   9.08×10^−17^
   AA                              170 (0.226)     643 (0.105)                                       3.883 (3.081 to 4.893)   1.30×10^−30^
   Risk allele (A)                 734 (0.489)     4015 (0.328)                                      1.981 (1.774 to 2.212)   6.35×10^−34^
  rs1867277                                                                                                                   
   GG                              159 (0.211)     2290 (0.376)                                      Reference                
   AG                              398 (0.529)     2879 (0.473)                                      1.991 (1.638 to 2.428)   3.99×10^−13^
   AA                              196 (0.260)     918 (0.151)                                       3.074 (2.446 to 3.864)   5.97×10^−23^
   Risk allele (A)                 790 (0.525)     4715 (0.387)                                      1.749 (1.569 to 1.950)   5.90×10^−24^
  rs944289                                                                                                                    
   CC                              87 (0.116)      1003 (0.164)                                      Reference                
   CT                              332 (0.441)     2924 (0.478)                                      1.309 (1.019 to 1.582)   0.033
   TT                              334 (0.444)     2193 (0.358)                                      1.755 (1.365 to 2.276)   4.36×10^−6^
   Risk allele (T)                 1000 (0.664)    7310 (0.597)                                      1.330 (1.188 to 1.489)   6.95×10^−7^

SNP, single nucleotide polymorphism.

Are there multiple risk alleles on chromosome 9q22?
---------------------------------------------------

The 9q22 variants associated with TC risk, rs965513 and rs1867277, were originally reported by independent and non-overlapping GWA and candidate gene studies.[@b3] [@b5] Other studies have not considered whether these SNPs represent independent signals of association. We performed unconditional logistic regression analyses incorporating rs1867277 and rs965513 genotypes as variables and sex as a covariate in the model. Both the rs965513 (p=2.34×10^−13^, OR=1.74) and rs1867277 (p=0.008, OR=1.21) association signals decreased but remained significant. We then reconstructed haplotypes at these two loci and estimated the ORs associated with having each one of three possible risk haplotypes (haplotype 2=rs965513A-rs1867277A, haplotype 3=rs965513G-rs1867277A, and haplotype 4=rs965513A-rs1867277G, [table 2](#tbl2){ref-type="table"}) compared with the non-risk haplotype (haplotype 1=rs965513G-rs1867277G). As expected, carrying the haplotype with both risk alleles (haplotype 2) increased disease risk significantly (p=2.19×10^−36^, OR=2.09). Carrying haplotypes with either one risk allele at rs965513 (haplotype 3) or at rs1867277 (haplotype 4) also increased risk, although the association signal for the haplotype 3 was weaker (P~haplotype\ 3~=0.07, OR~haplotype\ 3~=1.19 and P~haplotype\ 4~=0.0001, OR~haplotype\ 4~=1.61, [table 2](#tbl2){ref-type="table"}).

###### 

Thyroid cancer risk associated with different haplotypes, defined by rs965513 and rs1867277 alleles, at chromosome 9q22

  Haplotype   rs965513   rs1867277   Frequency   OR      p Value                  
  ----------- ---------- ----------- ----------- ------- ------------------------ --------------
  1           G          G           0.413       0.561   Reference                
  2           A          A           0.429       0.276   2.139 (1.902 to 2.407)   2.19×10^−35^
  3           A          G           0.097       0.111   1.189 (0.978 to 1.485)   0.077
  4           G          A           0.061       0.052   1.612 (1.264 to 2.037)   0.0001

Haplotype frequencies were estimated using Haploview (<http://www.haploview.org/>). Only samples with full data at both loci were used for the analyses (761 cases and 6085 controls).

We also estimated the risk associated with 'diplotypes' at each the two 9q22 loci. [Table 3](#tbl3){ref-type="table"} shows the genotype frequencies at the two SNPs and the ORs associated with the nine possible diplotypes. Individuals with the four risk alleles at both loci (∼7.4% of the general population) had a 4.45-fold higher risk than non-carriers (∼31.5% of the population), with the other diplotypes having intermediate risk levels, principally dependent on rs965513 ([table 3](#tbl3){ref-type="table"}).

###### 

Thyroid cancer risk associated with different genotype combinations (diplotypes) at rs965513 and rs1867277

  rs965513   rs1867277     Frequency (%)   OR (95% CI)              p Value                   
  ---------- ------------- --------------- ------------------------ ------------------------- -------
  GG         GG            123 (0.162)     1917 (0.315)             Reference                 
  AG         60 (0.079)    744 (0.122)     1.257 (0.897 to 1.747)   0.174                     
  AA         7 (0.009)     73 (0.012)      1.494 (0.568 to 3.333)   0.336                     
  AG         GG            33 (0.043)      355 (0.058)              1.449 (0.939 to 2.183)    0.071
  AG         300 (0.394)   1960 (0.322)    2.385 (1.908 to 2.995)   6.62×10^−16^              
  AA         63 (0.083)    394 (0.065)     2.491 (1.774 to 3.473)   1.10×10^−7^               
  AA         GG            4 (0.005)       17 (0.003)               3.663 (0.883 to 11.465)   0.036
  AG         42 (0.055)    174 (0.029)     3.759 (2.497 to 5.580)   4.44×10^−10^              
  AA         129 (0.170)   451 (0.074)     4.455 (3.379 to 5.876)   8.50×10^−27^              

The risk alleles are rs965513A and rs1867277A.

These analyses showed that the two SNPs did not simply and efficiently tag a single high-risk haplotype on 9q22. However, they did not distinguish between the existence of multiple independent risk alleles at 9q22 and a third 'causal' variant tagged in complex fashion by both rs1867277 and rs965513. To undertake a limited examination of the latter possibility, we searched for SNPs in high/moderate LD (*r*^2^\>0.5) with both rs1867277 and rs965513 in the most recent release of the 1000 Genomes Project (phase 1, interim release, 11 May 2011, n=762 European samples). We identified four such SNPs (rs10124220, rs7848973, rs6478413, and rs1443432, supplementary table 2, supplementary figure 1). However, none of these polymorphisms lay at a site with evidence of functional importance (data not shown). We found no evidence for a role of non-synonymous variants within any of the seven nearby 9q22 genes (supplementary figure 1).

TC is associated with variation at 8q24 under a recessive model
---------------------------------------------------------------

We found evidence that rs6983267G was associated with TC in the UK population ([table 1](#tbl1){ref-type="table"}). Interestingly, and unlike previous findings in other cancer types, rs6983267G was associated with TC risk according to a recessive model ([tables 1](#tbl1){ref-type="table"} and [4](#tbl4){ref-type="table"}). We found no difference in risk between non-carriers and heterozygotes (OR=1.01, 95% CI 0.83 to 1.24, p=0.921, [table 1](#tbl1){ref-type="table"}), but a significantly increased risk when homozygous carriers (GG) were compared to non-carriers (p=0.016, OR=1.140, [table 1](#tbl1){ref-type="table"}), to heterozygotes (p=0.009, OR=1.27, [table 1](#tbl1){ref-type="table"}), and to non-carriers/heterozygotes (p=0.004, OR=1.26, [table 4](#tbl4){ref-type="table"}). Wokolorczyk *et al*[@b6] had previously found relatively weak evidence of association between TC and the rs6983267 SNP in the Polish population (p=0.04, OR=0.78, 95% CI 0.63 to 1.00). We carried out a meta-analysis of the Polish data and our data and found enhanced support for an association between rs6983267G and TC risk, with no evidence of inter-study heterogeneity (P~*meta*~=6.64×10^−4^, per allele OR~meta~=1.15, 95% CI 1.06 to 1.25, P~heterogeneity~=0.841, supplementary figure 2). The meta-analysis continued to support a recessive effect of the rs6983767G allele on risk (OR \>1.2, p\<0.004, [table 4](#tbl4){ref-type="table"}) and found no difference in risk between heterozygous and non-carriers (OR=1.087, p=0.142, [table 4](#tbl4){ref-type="table"}).

###### 

Evidence that the association between rs6983267 and thyroid cancer risk is best explained by a recessive model

  Test              UK only                  Meta analysis of UK and Polish studies                            
  ----------------- ------------------------ ---------------------------------------- ------------------------ -------------
  GG vs (GT + TT)   1.266 (1.071 to 1.494)   0.004                                    1.250 (1.089 to 1.435)   7.64×10^−4^
  GG vs GT          1.262 (1.055 to 1.509)   0.009                                    1.215 (1.051 to 1.404)   0.004
  GT vs TT          1.010 (0.827 to 1.236)   0.960                                    1.087 (0.933 to 1.266)   0.142

Note that the risk allele homozygotes (GG) have significantly higher frequency compared with other genotypes combined (GT + TT) and with heterozygotes (GT). This is also the case for the GG versus TT test which is not shown. However, there is no evidence that heterozygotes are over-represented in cases (GT vs TT).

rs2910164 at the pre-miR-146a locus is not associated with TC
-------------------------------------------------------------

Using an allelic model, our study found no evidence of an association between rs2910164 and TC risk (P~*allelic*~=0.85, [table 1](#tbl1){ref-type="table"}). We confirmed the absence of associations between this SNP and TC in genotypic, dominant, recessive and trend models (p\>0.71 for all models, supplementary table 3). The previous report of an association between rs2910164 and papillary TC risk found a highly significant association between rs2910164 heterozygosity and disease (p=7×10^−7^, OR=1.62, 95% CI 1.3 to 2.0); unusually, both homozygote genotypes were protective.[@b4] We tested this model in our data and failed to replicate an association between rs2910164 heterozygosity and TC risk (p=0.784; supplementary table 3). When the analyses were restricted to the cases that had histologically verified papillary TC we also failed to detect association between rs2910164 and TC (p\>0.784 for all models, data not shown, supplementary table 3).

Combined effects of rs6983267, rs965513, rs1867277, and rs944289 on disease risk
--------------------------------------------------------------------------------

We carried out case-only and case-control pairwise analyses between all four risk SNPs associated with TC and found to no evidence for SNP--SNP interaction (details not shown). We then estimated the combined effects of the four SNPs on risk. To incorporate the effects of the two 9q22 markers in the combined risk analyses, we used the estimates obtained in our diplotype analyses ([table 3](#tbl3){ref-type="table"}). Using this information, we estimated that the risk for those individuals who are homozygous at 8q24, 9q22 and 14q13---comprising ∼1.7% of the UK population---is 9.96-fold higher compared with individuals who do not carry any risk allele at these loci (∼1.2% of the population, [table 5](#tbl5){ref-type="table"}). The risk homozygous at the four SNPs (17 cases and 41 controls, supplementary table 5) have a 17.08-fold higher chance of having TC (95% CI 3.776 to 159.323) when compared to non-risk homozygous (two cases and 84 controls, supplementary table 5).

###### 

Estimates to genotype relative risk at rs6983267, 9q22, and rs944289

  Locus                                            Non-carriers   Heterozygous   Homozygous carriers           
  ------------------------------------------------ -------------- -------------- --------------------- ------- -------
  rs6983267[\*](#table-fn1){ref-type="table-fn"}   0.236          NA             NA                    1.274   0.272
  9q22[†](#table-fn2){ref-type="table-fn"}         0.315          2.385          0.322                 4.455   0.074
  rs944289                                         0.164          1.309          0.478                 1.755   0.358
  Combined                                         0.012          3.122          0.210                 9.961   0.017

rs69833267 heterozygous do not have increased risk of thyroid cancer (see [tables 1](#tbl1){ref-type="table"} and [4](#tbl4){ref-type="table"}).

ORs and frequencies for the 9q22 markers were obtained from the diplotype analysis presented in [table 3](#tbl3){ref-type="table"}. Population frequency from non-carriers, heterozygous and homozygous carriers is shown in [table 3](#tbl3){ref-type="table"}.

Contribution of 8q24, 9q22, and 14q13 variants to the familial risk of TC
-------------------------------------------------------------------------

We have shown that four variants at 8q24, 9q22, and 14q13 are associated with a significantly higher risk of TC in the UK population. We then determined the proportion of the sibling relative risk of TC that they explained (15). Using a TC sibling relative risk of 8.6 (2), we estimated that these four risk variants explain 10.9% of the sibling relative risk of TC. Under a conservative model that assumes the existence of a single risk variant at chromosome 9q22, these loci explain at least 6.6% of the disease heritability (supplementary table 4).

Discussion
==========

Using a relatively large sample set in a single, homogeneous European population, we confirmed associations between TC and SNPs on chromosomes 9q22 (rs965513 and rs1867277), 14q13 (rs944289), and 8q24 (rs6983267). However, we failed to replicate an association between SNP rs2910164 on 5q24 and TC risk.

The 9q22 SNPs rs965513 and rs1867277 have not previously been genotyped in the same samples. We have found that there is not a single TC risk haplotype on 9q22 that is perfectly denoted by rs965513 and rs1867277. Conversely, the association cannot be explained entirely by genotypes at only one of the two SNPs, although logistic regression analysis incorporating both SNPs did lead to a considerably reduced association signal for both SNPs, particularly rs1867277. We suggest, therefore, that rs965513 and rs1867277 tag a third variant (or variants) that is the functional variation near *FOXE1*. Perhaps contrary to the genetic data, Landa *et al*[@b5] showed that rs1867277A affected *FOXE1* transcript levels through the differential recruitment of the USF1/USF2 transcription factors and suggested that rs1867277 was a TC-causal SNP. Fine mapping studies at this site might benefit from the use of non-European samples. For example, the LD between rs965513 and rs1867277 is significantly weaker in populations of African (*r^2^*=0.01, *D*\'=0.078) or Asian (*r^2^*=0.00, *D*\'=0.014) ancestry (data from the 1000 Genomes Project). Finally, although challenging,[@b16] rare variants at *FOXE1* deserve further scrutiny.

Our study validated the association between TC and rs6983267 and extended the range of cancer types associated with this variant. Interestingly, however, we found that rs6983267G is associated with TC risk in a recessive fashion; all other rs6983267 cancer associations follow an allelic dosage model. Recessive cancer predisposition SNPs have rarely been found. In part, this probably reflects suboptimal power in GWA studies and our finding emphasises the role of candidate SNP analyses across cancer types. Given that rs6983267 itself may be functional in predisposition to colorectal and other cancers,[@b17] one possibility is that the true, recessive functional variation in TC is not rs6983267, but an SNP in strong LD with it.

The first association between TC and common genetic variants was found at the pre-miR-146a locus (4), a micro-RNA that is upregulated in thyroid tumours.[@b18] There was no good evidence in our study of an association between rs2910164 and TC risk under all models tested, including the heterozygous model that showed the disease association in the study of Jazdewski *et al*.[@b4] It is notable that deviations from Hardy-Weinberg equilibrium were present in the case genotypes of Jazdewski *et al*; it is not clear whether this was the result or the cause of the heterozygote association with TC risk. Other possible explanations for the differences between Jazdewski *et al*\'s study and our own include chance, systematic differences between cases and controls (whether related to ascertainment or technical issues) and population specific effects in either study.

The four validated TC risk SNPs explain an approximately 10-fold differential risk between those with all high risk alleles and those with all low risk alleles. Moreover, owing to the large effect size associated with the 9q22 SNPs, the four SNPs explain over 10% of the total sibling relative risk of TC, despite the fact that TC has one of the largest familial relative risks reported for any malignancy. It is highly plausible that future studies involving only a few thousand cases and controls could identify additional important common risk variants for this common disease.
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